Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
Dr. Reddy’s Laboratories released its quarterly report for the period ending December 31, 2024, presenting unaudited condensed consolidated interim financial statements in accordance with International Accounting Standards. The report, which has been reviewed by Ernst & Young Associates LLP, confirms the absence of material modifications necessary for compliance. It highlights challenges faced by the company, including risks associated with global operations, regulatory compliance, and competitive pressures in the generic medicines market. These factors could potentially impact the company’s future performance and stakeholder interests.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company headquartered in Hyderabad, India. It operates within the healthcare industry, primarily focusing on the development and commercialization of generic medicines. The company is engaged in providing a wide range of pharmaceutical services, including manufacturing, marketing, and distribution of pharmaceutical products across global markets.
YTD Price Performance: -5.55%
Average Trading Volume: 1,419,662
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.42B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.
